Genomic Testing

FOUNDATIONONE®Liquid CDx

FoundationOne® Liquid CDx is an extensively validated, comprehensive liquid biopsy test for solid tumours utilizing circulating tumour DNA (ctDNA).
  • USES
    FoundationOne Liquid CDx is suited for use in all solid cancers including NSCLC, breast, ovarian and prostate cancer
  • SAMPLE TYPE
    Two tubes of peripheral whole blood (8.5mL per tube)
  • RESULTS EXPECTED
    ≤10 days

What is FoundationOne Liquid CDx?

FoundationOne Liquid CDx is a liquid biopsy test that provides targeted gene results across 324 genes as well as microsatellite instability (MSI), and blood tumour mutational burden (bTMB) results, which can help inform next-steps for advanced-stage cancer patients using a minimally invasive sample type. By analyzing ctDNA with our comprehensive genomic profiling approach and providing curated reports, FoundationOne Liquid CDx may empower providers to make more informed clinical decisions even when tissue is not ideal.

Overview

FoundationOne Liquid CDx

  1. A single liquid biopsy test that assesses all four main classes of genomic alterations in 324* cancer-related genes across a wide range of solid tumours1,2
  2. Reports MSIa and bTMB, which can help inform the use of immunotherapies1,2.
  3. Reports Tumour Fraction as a measure of the likelihood of detecting genomic alterations in the liquid biopsy sample1,2.
  4. Requires only two 8.5mL tubes of blood

* 309 genes with complete exon coverage, 15 genes with select intronic or non-coding regions only

a. MSI status will be reported for samples determined to have high microsatellite instability.

Order FoundationOne Liquid CDx

We provide physicians with options for ordering FoundationOne Liquid CDx for patients including fax and phone. Healthcare providers must first complete a test requisition form to start the process and can expect results within 10 days from the time blood specimen is received at the lab location.
Order Genomic Test with Your Doctor

Patients

FoundationOne Liquid CDx is ordered by your healthcare provider. Our patient info kit has all the information you and your doctor need to discuss FoundationOne Liquid CDx testing.

Download Patient Brochure

Health Care Practitioners

FoundationOne Liquid CDx can be ordered by fax or by phone. Please review and complete the provider resources before ordering.

Order Now

Provider Resources

Questions? We’re here to help.

Contact Us

  1. FoundationOne Liquid CDx Technical Specifications, 2020.
  2. Woodhouse R et al. Manuscript submitted.

FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx are next-generation sequencing services performed by Foundation Medicine, Inc. at laboratories located in Cambridge, Massachusetts, USA. Hoffmann-La Roche Limited markets these services in Canada under an exclusive license from Foundation Medicine, Inc. The FoundationOne®CDx, FoundationOne®Heme and FoundationOne®Liquid CDx reports are prepared exclusively by Foundation Medicine, Inc., without Hoffmann-La Roche Limited’s involvement. The reports may include scientific information about experimental medicinal product(s) or uses that are not approved and/or available in Canada. Hoffmann-La Roche Limited does not endorse or recommend the unapproved use of any medicinal product. FoundationOne® and FoundationOne®CDx are registered trade-marks of Foundation Medicine, Inc., used under license.

Privacy Policy | Terms of Use | Cookie Preferences
© 2024 Hoffmann-La Roche Limited

This website contains information intended for a Canadian audience only, and may contain information or treatment options that are not valid or accessible in other countries. We are not responsible for the access or use outside of Canada of any information on this website which may not comply with laws and regulations applicable outside of Canada.

This website is neither intended nor designed to record or report adverse event information. If you have a suspected side effect or problem to report regarding a Roche product, please email [email protected] or call 1-888-762-4388. You can also report adverse events relating to any product to Health Canada directly by going to the Canada Vigilance Program website at https://www.canada.ca/en/health-canada/services/drugs-health-products/medeffect-canada/adverse-reaction-reporting.html.